Protox appoints new directors

Protox Therapeutics (TSX:PRX) is appointing William Rohn and Amit Sobti to the board. Mr. Rohn has over 30 years of experience as a senior executive in the pharmaceutical and biotech industry. He retired in January, 2005 as COO of Biogen-Idec, playing an instrumental role in the $6.8 billion merger of IDEC Pharmaceuticals and Biogen. Mr. [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

Protox holders okay Warburg investment

Shareholders of Protox Therapeutics (TSX:PRX) at a special meeting overwhelmingly approved a proposed investment of up to $35 million from private equity giant Warburg Pincus. An initial tranche of $10 million is expected to close by Nov. 23.  It would be followed by a further $25 million, subject to the FDA granting a special protocol [...]

Protox gets credibility boost from Warburg Pincus

An equity injection of up to $35 million from private equity giant Warburg Pincus represents a huge vote of confidence in Protox Therapeutics (TSX:PRX) and its lead PRX302 drug for enlarged prostate or benign prostatic hyperplasia (BPH), with the drug potentially able to target two other diseases: prostate cancer and prostatitis. “We went through an [...]

Warburg to invest up to $35 million in Protox

Two Warburg Pincus funds have agreed to invest up to $35 million in Protox Therapeutics (TSX:PRX), consisting of an initial tranche of $10 million and an additional tranche of $25 million, resulting in the funds having majority stake in Protox. “Warburg Pincus’ impressive track record of building substantial shareholder value, providing access to growth capital, [...]

Protox has positive six-month Phase 2b BPH results

Protox Therapeutics (TSX:PRX) has released positive six-month data from its Phase 2b TRIUMP study of its PRX302 drug in patients with moderate-to-severe benign prostatic hyperplasia. The study met its primary endpoint with a statistically significant improvement in International Prostate Symptom Score at day-90 for patients treated with PRX302 versus placebo and requires additional patient assessments [...]